The genetics of the polycystic ovary syndrome

Nature Clinical Practice Endocrinology and Metabolism

Volumn 3, Issue 2, 2007, Pages 103-111

  Urbanek, Margrit ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

CAPN10; CYP11A; D19S884; Genetics of complex diseases; Polycystic ovary syndrome

Indexed keywords

ANDROGEN; CALPAIN 10; CYTOCHROME P450; CYTOCHROME P450 11A; POLYPEPTIDE; UNCLASSIFIED DRUG;

ANDROGEN RELEASE; ANDROGEN SYNTHESIS; CHROMOSOME 19P; DINUCLEOTIDE REPEAT; DISEASE ASSOCIATION; EPIGENETICS; GENE LOCUS; GENE MAPPING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENETICS; HORMONE RELEASE; HUMAN; INSULIN RELEASE; OBESITY; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SAMPLE SIZE; TANDEM REPEAT; VARIABLE NUMBER OF TANDEM REPEAT;

CALPAIN; CHOLESTEROL SIDE-CHAIN CLEAVAGE ENZYME; CHROMOSOMES, HUMAN, PAIR 19; DINUCLEOTIDE REPEATS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSULIN; MINISATELLITE REPEATS; PEDIGREE; POLYCYSTIC OVARY SYNDROME;

EID: 33846463033     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0400     Document Type: Review

References (78)

1. Diamanti-Kandarakis E et al. (1999) A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 84: 4006-4011
2. Knochenhauer ES et al. (1998) Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83: 3078-3082
3. Sam S and Dunaif A (2003) Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab 14: 365-370
4. Yildiz BO et al. (2003) Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab 88: 2031-2036
5. Sam S et al. (2005) Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 90: 4797-4802
6. Sir-Petermann T et al. (2002) Prevalence of type II diabetes mellitus and insulin resistance in parents of women with polycystic ovary syndrome. Diabetologia 45: 959-964
7. Yilmaz M et al. (2005) Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome. Hum Reprod (Oxf) 20: 2414-2420
8. Kiddy DS et al. (1992) Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 36: 105-111
9. Norman RJ et al. (2004) Improving reproductive performance in overweight/obese women with effective weight management. Hum Reprod Update 10: 267-280
10. Moran LJ et al. (2004) Short term energy restriction (using meal replacements) improves reproductive parameters in polycystic ovary syndrome. Asia Pacific J Clin Nutr 13 (Suppl): S88
11. Moran L and Norman RJ (2004) Understanding and managing disturbances in insulin metabolism and body weight in women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 18: 719-736
12. Norman RJ et al. (2002) The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 13: 251-257
13. Cooper HE et al. (1968) Hereditary factors in Stein-Leventhal syndrome. Am J Obstet Gynecol 100: 371-387
14. Givens JR (1988) Familial polycystic ovarian disease. Endocrinol Metab Clin N Am 17: 771-783
15. Hague W et al. (1988) Familial polycystic ovaries: a genetic disease. Clin Endocrinol 29: 593-605
16. Ferriman D and Purdie AW (1979) The inheritance of polycystic ovarian disease and a possible relationship to premature balding. Clin Endocrinol 11: 291-300
17. Carey AH et al. (1993) Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clin Endocrinol 38: 653-658
18. Legro RS et al. (1998) Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 95: 14956-14960
19. Kahsar-Miller M and Azziz R (1999) Heritability and the risk of developing androgen excess. J Steroid Biochem Mol Biol 69: 261-268
20. Jahanfar S et al. (1997) A twin study of polycystic ovary syndrome and lipids. Gynecol Endocrinol 11: 111-117
21. Kahsar-Miller MD et al. (2001) Prevalence of polycystic ovary syndrome (PCOS) in first degree relatives of patients with PCOS. Fertil Steril 75: 53-58
22. Vink J et al. (2005) Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab 91: 2100-2104
23. Urbanek M et al. (1999) Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci USA 96: 8573-8578
24. Escobar-Morreale HF et al. (2005) The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 26: 251-282
25. Newton-Cheh C and Hirschhorn JN (2005) Genetic association studies of complex traits: design and analysis issues. Mutat Res 573: 54-69
26. Hirschhorn JN (2005) Genetic approaches to studying common diseases and complex traits. Pediatr Res 57: 74R-77R
27. Hirschhorn JN and Daly MJ (2005) Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 6: 95-108
28. Hattersley AT and McCarthy MI (2005) What makes a good genetic association study? Lancet 366: 1315-1323
29. Zawadzki JK and Dunaif A (1992) Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Polycystic Ovary Syndrome, 377-384 (Eds Dunaif A et al.) Boston: Blackwell Scientific
30. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19: 41-47
31. Altshuler D et al. (2000) The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26: 76-80
32. Grant SF et al. (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38: 320-323
33. Gharani N et al. (1997) Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 6: 397-402
34. Diamanti-Kandarakis E et al. (2000) Microsatellite polymorphism (tttta)(n) at -528 base pairs of gene CYP11α influences hyperandrogenemia in patients with polycystic ovary syndrome. Fertil Steril 73: 735-741
35. Daneshmand S et al. (2002) Overexpression of theca-cell messenger RNA in polycystic ovary syndrome does not correlate with polymorphisms in the cholesterol side-chain cleavage and 17α-hydroxylase/ C(17-20) lyase promoters. Fertil Steril 77: 274-280
36. San Millan JL et al. (2001) Role of the pentanucleotide (tttta)(n) polymorphism in the promoter of the CYP11a gene in the pathogenesis of hirsutism. Fertil Steril 75: 797-802
37. Gaasenbeek M et al. (2004) Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone. J Clin Endocrinol Metab 89: 2408-2413
38. Bell GI et al. (1982) The highly polymorphic region near the human insulin gene is composed of simple tandemly repeating sequences. Nature 295: 31-35
39. Pugliese A and Miceli D (2002) The insulin gene in diabetes. Diabetes Metab Res Rev 18: 13-25
40. Waterworth DM et al. (1997) Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet 349: 986-990
41. Michelmore K et al. (2001) Clinical features in women with polycystic ovaries: relationships to insulin sensitivity, insulin gene VNTR and birth weight. Clin Endocrinol (Oxf) 55: 439-446
42. Calvo RM et al. (2002) Insulin gene variable number of tandem repeats regulatory polymorphism is not associated with hyperandrogenism in Spanish women. Fertil Steril 77: 666-668
43. Powell BL et al. (2005) Analysis of multiple data sets reveals no association between the insulin gene variable number tandem repeat element and polycystic ovary syndrome or related traits. J Clin Endocrinol Metab 90: 2988-2993
44. Hanis CL et al. (1996) A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nat Genet 13: 161-166
45. Horikawa Y et al. (2000) Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 26: 163-175
46. Evans JC et al. (2001) Studies of association between the gene for calpain-10 and type 2 diabetes mellitus in the United Kingdom. Am J Hum Genet 69: 544-552
47. Tsai HJ et al. (2001) Type 2 diabetes and three calpain-10 gene polymorphisms in Samoans: no evidence of association. Am J Hum Genet 69: 1236-1244
48. Ehrmann DA et al. (2002) Relationship of calpain-10 genotype to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab 87: 1669-1673
49. Haddad L et al. (2002) Variation within the type 2 diabetes susceptibility gene calpain-10 and polycystic ovary syndrome. J Clin Endocrinol Metab 87: 2606-2610
50. Urbanek M et al. (2005) Candidate gene region for polycystic ovary syndrome on chromosome 19p13.2. J Clin Endocrinol Metab 90: 6623-6629
51. Tucci S et al. (2001) Evidence for association of polycystic ovary syndrome in Caucasian women with a marker at the insulin receptor locus. J Clin Endocrinol Metab 86: 446-449
52. Villuendas G et al. (2003) Association between the D19S884 marker at the insulin receptor gene locus and polycystic ovary syndrome. Fertil Steril 79: 219-220
53. Hata R et al. (2000) Association of functional microsatellites in the human type I collagen α2 chain (COL1A2) gene with systemic sclerosis. Biochem Biophys Res Commun 272: 36-40
54. Fenech AG et al. (2004) Novel polymorphisms influencing transcription of the human CHRM2 gene in airway smooth muscle. Am J Respir Cell Mol Biol 30: 678-686
55. Huang TS et al. (2003) Shortening of microsatellite deoxy(CA) repeats involved in GL331-induced down-regulation of matrix metalloproteinase-9 gene expression. Biochem Biophys Res Commun 300: 901-907
56. 2+ exchanger intron 2 activates splicing. Eur J Biochem 268: 1076-1083
57. Hui J et al. (2003) HnRNP L stimulates splicing of the eNOS gene by binding to variable-length CA repeats. Nat Struct Biol 10: 33-37
58. Abbott DH et al. (2002) Developmental origin of polycystic ovary syndrome-a hypothesis. J Endocrinol 174: 1-5
59. Abbott DH et al. (2005) Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum Reprod Update 11: 357-374
60. Foecking EM et al. (2005) Neuroendocrine consequences of prenatal androgen exposure in the female rat: absence of luteinizing hormone surges, suppression of progesterone receptor gene expression, and acceleration of the gonadotropin-releasing hormone pulse generator. Biol Reprod 72: 1475-1483
61. de Zegher F et al. (2006) Prenatal growth restraint followed by catch-up of weight: a hyperinsulinemic pathway to polycystic ovary syndrome. Fertil Steril 86: S4
62. Ibanez L et al. (2002) Reduced ovulation rate in adolescent girls born small for gestational age. J Clin Endocrinol Metab 87: 3391-3393
63. Ibanez L et al. (2002) Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism. J Clin Endocrinol Metab 87: 5702-5705
64. Ibanez L et al. (2001) Polycystic ovary syndrome after precocious pubarche: ontogeny of the low birthweight effect. Clin Endocrinol 55: 667-672
65. Ibanez L et al. (2006) Early development of adiposity and insulin resistance after catch-up weight gain in small-for-gestational age children. J Clin Endocrinol Metab 91: 2153-2158
66. Hickey TE et al. (2006) Epigenetic modification of the X chromosome influences susceptibility to polycystic ovary syndrome. J Clin Endocrinol Metab 91: 2789-2791
67. Mhatre AN et al. (1993) Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy. Nat Genet 5: 184-188
68. Tut TG et al. (1997) Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab 82: 3777-3782
69. Jakubiczka S et al. (1997) Mutations of the androgen receptor gene in patients with complete androgen insensitivity. Hum Mutat 9: 57-61
70. Jaaskelainen J et al. (2005) Androgen receptor gene CAG length polymorphism in women with polycystic ovary syndrome. Fertil Steril 83: 1724-1728
71. Legro R et al. (1994) Size polymorphisms of the androgen receptor among female Hispanics and correlation with androgenic characteristics. Obstet Gynecol 83: 701-706
72. Mifsud A et al. (2000) Androgen receptor gene CAG trinucleotide repeats in anovulatory infertility and polycystic ovaries. J Clin Endocrinol Metab 85: 3484-3488
73. Mohlig M et al. (2006) The androgen receptor CAG repeat modifies the impact of testosterone on insulin resistance in women with polycystic ovary syndrome. Eur J Endocrinol 155: 127-130
74. Hickey T et al. (2002) The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metab 87: 161-165
75. The International HapMap Consortium (2003) The International HapMap Project. Nature 426: 789-796
76. Altshuler D et al. (2005) A haplotype map of the human genome. Nature 437: 1299-1320
77. Pasternack JJ (1999) Discovering human disease genes. In An Introduction to Human Molecular Genetics, 218-219 (Ed. Pasternack JJ) Bethesda, MD: Fitzgerald Science Press
78. Metzker ML (2005) Emerging technologies in DNA sequencing. Genome Res 15: 1767-1776